Cart contains    items
SEARCH

  |
  |  
  |  
  |  
  |  
  |  
 
Browse by molecule: [A]  [B]  [C]  [D]  [E]  [F]  [G]  [H]  [I]  [J]  [K]  [L]  [M]  [N]  [O]  [P]  [Q]  [R]  [S]  [T]  [U]  [V]  [W]  [X]  [Y]  [Z]  

Mouse EGFL7 Recombinant

EGF

accession:  Q9QXT5
   Size A     5ug   $ 160
   Size B      25ug  $470
   Size C      500ug  $ 4700
Domain  :  EGF,EMI
Gene  :  EGFL7
Catalog no. :  RKQ9QXT5
Source:
DNA sequence encoding mature chain of Mouse EGFL7(VE-Statin)  isoform-1 to a C-terminal polyHis tag was expressed in Insect cells.

 
Molecular weight:

Recombinant Mouse EGFL7  is a monomer consisting of 273 amino acid residue , and migrates as an approximately 33 kDa protein under reducing conditions in SDS-PAGE.

 
Purity:
>90%, as determined by SDS-PAGE

 
Biological Activity:
The activity was determined by the ability to support adhesion of HUVEC cells.

 

Protein Sequence:

  10 20 30 40 50 60

MWGSGELLVA WFLVLAADGT TEHVYRPSRR VCTVGISGGS ISETFVQRVY QPYLTTCDGH 

        70         80         90        100        110        120 
RACSTYRTIY RTAYRRSPGV TPARPRYACC PGWKRTSGLP GACGAAICQP PCGNGGSCIR 

       130        140        150        160        170        180 
PGHCRCPVGW QGDTCQTDVD ECSTGEASCP QRCVNTVGSY WCQGWEGQSP SADGTRCLSK 

       190        200        210        220        230        240 
EGPSPVAPNP TAGVDSMARE EVYRLQARVD VLEQKLQLVL APLHSLASRS TEHGLQDPGS 

       250        260        270 
LLAHSFQQLD RIDSLSEQVS FLEEHLGSCS CKKDL 
(*)Complete precursor sequence shown, expressed chain highlighted
 
Endotoxin:
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/µg(1EU/µg).

 
Presentation:
Recombinant Human EGFL7  was lyophilized from a 0.2 μm filtered PBS solution pH 7.4.

 
Reconstitution:
A quick spin of the vial followed by reconstitution in distilled water to a concentration not less than 0.1 mg/mL. This solution can then be diluted into other buffers.

 
Storage:
The lyophilized protein is stable for at least 2 years from date of receipt at -20° C.
Upon reconstitution, this cytokine can be stored in working aliquots at 2° - 8° C for one month, or at -20° C for six months, with a carrier protein without detectable loss of activity.

Avoid repeated freeze/thaw cycles.

 
Usage:
This cytokine product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.

 

EGFL7

EGFL7 is an 30 kDa secreted protein that contain an Emilin-like (EMI) domain, and 2 epidermal growth factor (EGF) domains, one of which binds calcium. Based on these domains, it has been hypothesized that EGFL7 may self-assemble like extracellular matrix (ECM) proteins and, thus, could incorporate into ECM. EGFL7 has been reported to stimulate cell adhesion as well as motility in a manner similar to ECM proteins. EGFL7 has been shown to be primarily expressed by developing ECs but also by primordial germ cells and some central nervous system neurons. Interestingly, EGFL7 expression markedly decreases in ECs in postnatal life, but can be strongly up-regulated after various tissue injuries that lead to increased angiogenic responses.

Related Publications:
EGFL7: a unique angiogenic signaling factor in vascular development and disease
Blood, Dec 2011; 10.1182/blood-2011-10-322446.
EGFL7 promotes tumor escape from immunity by repressing endothelial cell activation
Cancer Res., Dec 2011; 71: 7176 - 7186.
gene expression profiling of placentae from women with early- and late-onset pre-eclampsia: down-regulation of the angiogenesis related genes acvrl1 and EGFL7 in early-onset disease
Mol. Hum. Reprod., Oct 2011; 10.1093/molehr/gar067.
population pharmacokinetic (pk) analysis supports fixed dosing for the humanized monoclonal antibody (humab) anti-EGFL7 (megf0444a) administered intravenously in patients with advanced solid tumors.
ASCO Meeting Abstracts, May 2011; 29: 2586.
a phase ib dose-escalation study of the safety, pharmacokinetics (pk), pharmacodynamics (pd), and antitumor activity of the humanized monoclonal antibody (humab) anti-EGFL7 (megf0444a) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.
ASCO Meeting Abstracts, May 2011; 29: 2514.




by class:
Cytokines
Chemokines
Growth factors
CD markers
Viral Antigens
Other
by species:
Human
mouse
Rat
Antibodies:
Purified Polyclonal
Related Products:
product_icon_7.jpg Rabbit anti VEGF Polyclonal
product_icon_7.jpg Monoclonal mouse anti human VEGF
product_icon_8.jpg Human Epidermal Growth Factor Recombinant
product_icon_8.jpg Human VEGF 165AA Recombinant (E.Coli)
product_icon_8.jpg Mouse Epidermal Growth Factor Recombinant
product_icon_8.jpg Mouse VEGF 164AA Recombinant (E.Coli)
product_icon_8.jpg Human Endocrine Gland Vascular Endothelial Growth Factor Recombinant
product_icon_8.jpg Mouse VEGF 120AA Recombinant (E.Coli)
product_icon_8.jpg Human VEGF 165AA Recombinant (CHO Cell)
product_icon_8.jpg Mouse VEGFR2 Recombinant, Fc
product_icon_8.jpg Mouse VEGFR2 Recombinant
product_icon_8.jpg Human VEGFR2 Recombinant, Fc
product_icon_8.jpg Human VEGFR2 Recombinant
product_icon_8.jpg Mouse VEGF 164AA Recombinant (CHO Cell)
product_icon_8.jpg Human VEGF 121AA Recombinant (CHO Cell)
product_icon_8.jpg Human EGFR (erbb1) Recombinant , Biotinylated
product_icon_8.jpg Human VEGF 165AA Recombinant (CHO Cell), Biotinylated
product_icon_8.jpg Human VEGF 121AA Recombinant (CHO Cell), Biotinylated
product_icon_7.jpg Rabbit anti VEGFR2 Polyclonal
product_icon_8.jpg Human EGFL7 Recombinant
product_icon_8.jpg Mouse EGFL7 Recombinant
product_icon_8.jpg Human EGFR (erbb1) Recombinant
product_icon_8.jpg Rat Epidermal Growth Factor Recombinant
 
 
 
Item name Size Quantity Price(USD) Remove
checkout
Cart Total $